St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Rhabdoid tumor predisposition syndrome is a rare genetic disorder. It increases a person’s risk of developing a kind of fast-growing malignant tumor called a rhabdoid tumor. These tumors often grow in the brain, spinal cord, and kidney. They may also develop in the soft tissues, lungs, skin, and heart. These tumors are most common in children.
People with rhabdoid tumor predisposition syndrome also have a higher risk of developing non-cancerous tumors that grow along the nerves, called schwannomas. Schwannomas may cause painful lumps or tingling and numbness in some areas of the body. These tumors are more common in adults.
Not all people with rhabdoid tumors have rhabdoid tumor predisposition syndrome. When rhabdoid tumors develop in people without rhabdoid tumor predisposition syndrome, the tumors are called sporadic rhabdoid tumors. Only 30–35% of people (about 1 in 3) with rhabdoid tumors have rhabdoid tumor predisposition syndrome.
People with rhabdoid tumor predisposition syndrome have a higher risk of developing rhabdoid tumors than people in the general population. This risk is highest in young childhood and decreases after age 5. Older children and adults with rhabdoid tumor predisposition syndrome may have an increased risk of developing schwannomas.
Although people with rhabdoid tumor predisposition syndrome are at higher risk for tumors, some people never develop them. Doctors do not understand why some people with rhabdoid tumor predisposition syndrome develop tumors and some do not. Researchers have only recently started studying this genetic disorder. Further studies may help doctors to better understand the risks.
Often this syndrome is caused by changes in a gene called SMARCB1 (also called INI1), or less commonly by changes in a gene called SMARCA4 (BRG1). When a gene change causes a disorder or disease, it is called a gene mutation. Genes carry information telling cells in the body how to function. The SMARCB1and SMARCA4 genes help to control how cells grow, divide, and die.
Most people without rhabdoid tumor predisposition syndrome carry 2 working copies of the SMARCB1 or SMARCA4 gene in their cells. Cells from people with rhabdoid tumor predisposition syndrome carry 1 working copy of SMARCB1 or SMARCA4 and 1 mutated copy.
A few children with rhabdoid tumor predisposition syndrome inherit their mutation from a parent who also has the syndrome. But most children have a new SMARCB1 or SMARCA4 mutation that did not come from a parent. These children have no history of the syndrome in their family. In these cases, the gene change either happened in an egg or sperm cell that formed the child. Or the changes happened in one of the child’s cells during pregnancy. These children are the first in their families to have rhabdoid tumor predisposition syndrome.
No matter how children acquired the gene mutation, people with rhabdoid tumor predisposition syndrome have a 50% (or 1 in 2) chance of passing it on to their children.
A health care provider may suspect that your child has rhabdoid tumor predisposition syndrome after studying their medical and family cancer history.
This information helps the health care provider and the genetic counselor know if:
Your provider or genetics counselor may recommend SMARCB1 or SMARCA4 genetic testing if they suspect this condition.
Learn more about genetic testing.
A blood or tumor tissue sample is sent to a genetic testing lab. The lab runs genetic tests that look for changes in the SMARCB1 or SMARCA4 gene.
If your child has a SMARCB1 or SMARCA4 mutation, the genetic counselor will work with your family to:
Parents may choose to do prenatal testing to find out if a pregnancy is affected with a known SMARCB1 or SMARCA4 mutation. Testing may take place either before pregnancy occurs or during pregnancy.
You should work with a genetic counselor to review the pros and cons of the test. The genetic counselor can also help you prepare for the test results.
Testing before pregnancy is called preimplantation genetic testing (PGT). This special type of genetic testing is done along with in vitro fertilization (IVF). PGT tests embryos for a known SMARCB1 or SMARCA4 mutation before a provider places the embryo into the uterus.
Testing during pregnancy can help providers see if a pregnancy has a known SMARCB1 or SMARCA4 mutation. A doctor gathers cells from the pregnancy in 1 of 2 ways:
After tissue collection, the lab checks the sample for the SMARCB1 or SMARCA4 mutation.
Both tests carry minor risks. Discuss risks with an experienced health care provider or a genetic counselor.
Take time to think carefully about the benefits and risks of genetic testing. Speak with a genetic counselor before testing. If you decide to get tested, talk with your health care provider or a genetic counselor about your results so you can understand what they mean.
Sometimes, children or adults with rhabdoid tumor predisposition syndrome feel sad, anxious, or angry after getting their test results. Parents may feel guilty if they pass a SMARCB1 or SMARCA4 gene mutation to 1 or more of their children. People with a SMARCB1 or SMARCA4 gene mutation may also have trouble getting disability or life insurance.
Read more about genetic discrimination.
People with the syndrome should be monitored and have follow-up with a health care provider who knows the condition well.
Regular physical checkups and screenings are important. That way, any tumor that develops can be found early and at the most treatable stage.
Some health care providers recommend that people with this condition have a brain MRI exam and an abdominal ultrasound as soon as they are diagnosed, and then regularly after that. An MRI uses magnetic fields and radio waves to make images of the inside of the body. Ultrasound uses sound waves to make images of the inside of the body.
Screening recommendations may change as we learn more about this syndrome. This condition is rare and complex. People with the diagnosis should be cared for by an experienced health care team.
People of any age with rhabdoid tumor predisposition syndrome have a higher risk of cancer. They should monitor their health and adopt healthy habits.
Watch for signs and symptoms that could signal cancer:
It is important to seek medical help if anything unusual appears.
Habits that will help you maintain a healthy lifestyle include:
The St. Jude Cancer Predisposition Program is dedicated to diagnosing and screening children with a genetic predisposition for cancer. Our program offers the best clinical care possible. We engage in cutting-edge research to gain more information about genetic disorders and cancer, and to improve the care and treatment for patients who are affected by these conditions. Learn more about the Division of Cancer Predisposition at St. Jude.
Our genetic counselors, clinicians, genetics nurse practitioners, and research assistants work together to provide patients with:
Rhabdoid tumor predisposition syndrome increases your child’s risk of cancer.
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults who have cancers associated with rhabdoid tumor predisposition syndrome.
Study goal:
The main goal of this study is to test new experimental drugs in hopes of finding a treatment that may work against tumors that have come back or that have not responded to standard therapy in children, adolescents and young adults.
Age:
12 months to 30 years old
Study goal:
To learn more about participants beliefs, attitudes, and questions about gene therapy to help make web-based resources to share information. This could help patients make treatment decisions.
Age:
18 to 35 years old with rare genetic diseases
Study goal:
The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.
Study goal:
To provide a high-quality repository of tumor and normal samples to facilitate translational research performed by St Jude faculty and their collaborators
Study goal:
1) Test each patient for hundreds of gene variations that might be important for drug use. All of the gene test results will be in the research laboratory, but as time goes on, the study will evaluate scientific evidence and selectively move test results for a few genes into the medical record if the evidence strongly shows that the result can help in better prescribing of drugs for patients; 2) Estimate how often pharmacogenetic test results are moved from research tests into a patient’s medical record; 3) Use methods to choose which of these tests should be put in the medical record; 4) Use computer-based tools in the electronic medical record to help doctors use gene test results when prescribing drugs; 5) Share feelings and concerns of patients and their families about gene test information being put in their medical record.
Study goal:
The main purpose of this trial is to learn about the genetic causes of cancer.
Age:
Younger than 50 years old
Study goal:
To collect data about how Friedreich’s ataxia progresses over time and affects the daily life of patients.
Age:
Any
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334
If you have questions about the Genetic Predisposition Clinic and care for rhabdoid tumor predisposition syndrome, email our team at GPTeam@stjude.org.